The US Food and Drug Administration is requesting that manufacturers pull all prescription and over-the-counter ranitidine drugs, known by the brand name Zantac, from the market immediately, the agency announced on Wednesday.
The FDA noted that an ongoing investigation has determined that levels of a contaminant in the heartburn medications increase over time and when stored at higher-than-normal temperatures, pose a risk to public health.
The contaminant, N-nitrosodimethylamine or NDMA, is a probable human carcinogen and the FDA has been investigating levels of it in ranitidine since the summer of 2019.
The complete article can be accessed here.
Cohen Milstein is currently representing plaintiffs in a class action related to this very issue. The case is named: Bernardo, et al. v. Pfizer, Inc., et al., Case No. 9:20-cv-80249-RLR (S.D. Fla.).
If you would like further information on this case or to potentially join this case, please contact: Catherine MacCarthy, the paralegal assigned to the Zantac class action, at firstname.lastname@example.org or +1.561.515.2602 or complete the Zantac case investigation page here.